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ABSTRACT 
 
CHEVONNE DARICE EVERSLEY:  Integrative Genomic Analysis of Sporadic 
Colorectal Cancer 
(Under the direction of Dr. David Threadgill) 
 
 
Colorectal cancer is one of the leading causes of cancer deaths in the westernized 
world.  The great majority of these cases are sporadic occurrences with a familial genetic 
component reported.  Multiple susceptibility alleles, dietary, and environmental risk 
factors combine to determine individual predisposition. Attempts to map colon cancer 
susceptibility alleles in the human population have proven difficult due to failure to 
achieve statistical significance or have resulted in the identification of several weak 
alleles with limited clinical significance.  However, a number of low penetrance 
susceptibility alleles have been identified in mouse studies of segregating populations.  
We propose the use of a more diverse backcross population to identify additional 
susceptibility to colon cancer (Scc) modifiers as current loci have been realized with 
limited genetic diversity on common inbred strains.  
 With the inclusion of the Mus spretus strain, the azoxymethane (AOM) model of 
sporadic human colorectal cancer mimics the heterogeneity, pathology, and molecular 
changes evident in human populations.  In contrast to previous studies, we seek to expand 
on identify modifying loci and wish to extend our knowledge to reconstruct cancer 
specific networks and the interactions occurring therewith.  Using classical genetic 
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mapping techniques we can begin to visage the location of genes controlling the most 
variance, or strong effect modifiers.  Two-dimensional epistatic scans enable us to 
identify additional small effect modifying loci and begin the loose network recreation. 
These results are combined with a systems biology approach, linking transcript 
expression with genomic variation allowing us to identify the major components of a 
susceptibility network and guide candidate gene selection.  We conclude that these efforts 
will assist in susceptible patient detection and pharmacogenetic targeting of the most 
critical risk alleles.   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Abstract 
Inherited genetic mutations cause a small percentage of all cancers in the United 
States.  The combination of risk factors and accumulated low penetrance susceptibility 
alleles are the determinants of an individual’s predisposition.  Identifying these risk 
alleles, particularly in colorectal cancer (CRC), a leading cause of cancer deaths, is of 
great importance. We report using the laboratory mouse and the powerful classical 
genetics mapping approach to identify novel susceptibility to colon cancer loci (Scc) and 
their associated networks.  Our study mimics sporadic CRC by exposing a genetically 
diverse mouse population to a colon specific carcinogen, azoxymethane.  In addition, we 
extend our understanding of CRC susceptibility by applying systems genetics to clarify 
the genetic interactions and cancer specific networks. 
The combination of genomics with classical genetics produced the field of 
genetical genomics, which is now expanding to systems genetics by integrating multiple, 
systems-level biomolecular data in the context of segregating genetic populations. This 
new integrative field has the power to elucidate molecular networks associated with 
biological phenotypes by anchoring variability in networks to natural genetic variants. As 
initial applications of this technology was transcriptional profiling, which is providing 
new insights into the genetic networks underlying normal and disease states. Classical 
and systems genetics have enabled us to elucidate CRC susceptibility networks and the 
cellular re-wiring that occurs during cancer development. These approaches offer the 
possibility to identify and pharmaceutically-target networks that are cancer-specific, 
resulting in more effective, and safer anti-cancer drugs. 
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Introduction 
Differential susceptibility to the development, progression, and treatment of 
cancer is due to an intricate interplay between heredity, the environment, and stochastic 
somatic events. Although technological advances have enabled greater numbers of genes 
and environmental variables to be analyzed, the fraction of potential combinations that 
can be concurrently analyzed is still greatly restricted and is usually restricted to variables 
selected a priori based upon inferences from their potential role in cancer.  While these 
hypothesis-driven methods have provided a wealth of knowledge about the basic biology 
of cancer and have contributed to the tremendous advances in recent years, particularly 
for the development of molecule-targeted therapeutics, they are limited to analyzing a 
single gene, or at most, a handful of genes simultaneously.  However, genes and their 
downstream macromolecules, like RNA or protein, do not function in isolation, but rather 
as members of complex inter-related networks comprised of hundreds, potentially 
thousands, of components.  Mutations, deletions, changes in epigenetic regulation, or 
constitutional polymorphisms that alter or modulate the function of single genes can 
radiate within pathways impacting networks in a pleiomorphic manner. Recent genome-
wide association studies in humans have revealed that cancer susceptibility is polygenic 
with polymorphisms in many genes contributing to differential cancer susceptibility. 
Consequently, the application of systems genetics approaches to computationally model 
pleiomorphic changes that occur during cancer development will be essential in order to 
“reverse engineer” cancer susceptibility networks for the identification of critical nodes 
that regulate individual cancer susceptibility and for the development of novel therapeutic 
targets based upon sensitive nodal points within cancer susceptibility networks. 
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Classical Genetic Approaches 
 The foundation of genetic mapping rests on identifying the genomic location of 
allelic variants controlling phenotypic differences like differential susceptibility to 
cancer. In 1915 Thomas Morgan and Alfred Sturtevant created the first linkage map 
using the model organism Drosophila1. The Mechanism of Mendelian Heredity and 
“Chromosome Theory of Heredity” in 1920 provided scientific support and a plausible 
explanation for genetic inheritance 2.  The frequency of genetic recombination between 
homologous chromosomes allowed determination of the relative distance between genes 
responsible for differences in phenotypic traits.  Nearly half century later, Morton 
developed a mathematical model which includes the recombination frequency observed 
in a population as evidence of linkage to a single gene3.  
 Not all phenotypic characteristics are due to Mendelian inheritance of a single 
gene.  Rather traits with quantifiable variance in phenotypes, such as those responsible 
for susceptibility to most diseases like cancer, are often the consequence of polygenic 
inheritance. Quantitative trait loci (QTL) mapping is the process of statistically 
associating the measurement of traits to regions of the genome containing polymorphisms 
that quantitatively change the trait measurements. The resolving potential of QTL 
mapping is limited by the experimental population size, the amount of recombination, 
and marker density. This classical technique has led to the discovery of countless novel 
genes by narrowing the genomic interval and providing a reasonable starting point for 
fine mapping. 
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 Great strides have been made in cancer research by utilizing linkage and fine 
mapping techniques in combination with mouse models and cancer specific carcinogens 
towards the identifications of oncogenes, tumor supressors, and candidate genes. A 
number of loci involved in sporadic and familial colon cancer have led to the isolation of 
genes using these methods. In 1987, APC, the gene responsible for Familial 
Adenomatous Polyposis4, was localized to human chromosome 5 by linkage analysis. 
Several years later, MSH2 mouse homologue was mapped and used to confirm the 
identification of the causative gene in Hereditary Nonpolyposis Colorecal Cancer on 
human chromosome 25,6.  More recently, attention has turned to identifying the loci 
responsible in sporadic CRC. A number of susceptibility to colon cancer loci (Scc) were 
identified by fine mapping using a recombinant congenic strain derived from BALB/C 
and STS 7-10.  Of the 15 Scc loci, only Scc1 has been cloned and mapped resulting in 
Ptprj as a candidate gene.11 Although Scc1 was reported in 19967 and Ptprj was identified 
in 200211, the gene has yet to be conclusively confirmed as a susceptibility modifier of 
colon cancer, or more recently, breast cancer12-15. 
 The ability to use QTL mapping to narrow a genomic interval to 20 cM is still 
considerably large when 1cM generally represents 1 million base pairs. Fine mapping 
utilizes similar linkage analysis theory, identifying a conserved region among related 
disease affected individuals to narrow an interval to approximately 1-2cM so that a 
candidate gene can be cloned and identified.  Although there are added benefits of 
marker-assisted selection, it is still a laborious activity in large genomes, requires the 
generation of additional progeny, and is dependent on rare recombination events. Scc1 
and Ptprj are examples of the exceptional time and difficulty associated with fine 
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mapping. Until recently, this step was required for selection of a candidate gene; 
however, as technology progresses, the role of fine mapping in candidate gene selection 
is being usurped by whole genome techniques. 
 
Genomic Variants in QTL Mapping  
Technological advances in the past 30 years have propelled mapping techniques 
from localizing genes on a chromosome to narrowing candidate genes to a 2 cM interval.  
Until the advent of molecular markers, QTL mapping was limited to genetic markers tied 
to observed characteristics. Restriction fragment length polymorphisms (RFLP) were the 
first markers that utilized restriction enzymes to cut specific DNA sequence or single 
base pair substitutions that differed between two strains. Genetic maps were created by 
associating the disorder in question with a given RFLP and measuring the recombination 
frequency between RFLP markers16.  
RFLP markers were replaced by simple sequence length polymorphisms (SSLPs), 
short tandem repeats in genomic sequence due to a higher level of heterozygosity 
detection, ease, and rate of the polymerase chain reaction (PCR) based method. SSLPs 
include minisatellite markers, tandem repeats up to 100 base pairs in length, and 
microsatellite markers, variable di and tri nucleotide repeats17.  These tools enabled high-
resolution mapping and therefore opened up analysis of variation at the single nucleotide 
level.   
Millions of single nucleotide polymorphisms, SNPs, exist between strains or 
individuals, making these evolutionarily conserved variants the most common genetic 
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variation.  This discovery has spurned the developmental of large-scale projects, 
particularly SNP genotyping technologies resulting in high-density genomic maps with 
SNPs as molecular markers of sequence variation. SNPs act as both genetic markers 
narrowing causative loci searches to more manageable genomic intervals and are the 
causative alleles influencing gene expression. With the widespread use of dense SNP 
maps, increasing sample sizes and the ability to capture and map genome expression, the 
technological utility of fine mapping is dwindling.  
 
Variation in gene expression 
Technological spin-offs of the genome projects have resulted in the development 
of microarrays to measure global gene expression variation and by implication, 
differences in physiological states. Numerous comparative studies have been performed 
to identify a network of cancer subtypes in differentially regulated genes between normal 
tissue and tumors. New data suggests that in addition to somatic oncogenic mutations, 
inter tumor variation may be due to constitutional genetic variation among individuals 
who develop cancers. Furthermore, the expressivity of oncogenic mutations are often 
modified or modulated by constitutional genetic polymorphisms present elsewhere in the 
genome.  These polymorphic genes, also known as modifiers, may subtly alter pathway 
function through relatively minor perturbations of gene function or concentrations 
influencing susceptibility and oncogenic potential.  
The discussions involving the potential for cataclysmic events to be caused by 
multiple small pleiomorphic changes were initially demonstrated in yeast18,19.  High 
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throughput genome-scale tools captured significant inter-individual differences in the 
level of steady-state gene expression. These observations, under a single growth 
condition18, were quickly followed up with similar observations in yeast strains grown 
with and without copper sulfate20 and in human blood21. Whitney et al. showed donor-
specific patterns of gene expression that were influenced by proportions of different cell 
types present, such as gender, age, and the time of day the blood was drawn21.  This 
evidence lent further proof to the hypothesis that inter-individual variation plays a role in 
the development of cancers in predisposed individuals.  
 
Mapping differences in gene expression 
Combining quantitative measurement of gene expression using microarrays with 
classical genetic mapping provides a powerful strategy to identify not only potential 
candidates for modifier genes, but also construction and interrogation of molecular 
networks in which modifiers operate.  
The first application of this approach, termed genetical genomics22, occurred in 
yeast23.  A wild isolate of S. cerevisiae was crossed with a laboratory strain and genome-
wide linkage analysis queried the genetic control of gene expression anchored in DNA 
variants. Of 6215 genes analyzed, greater than one-fourth were differentially expressed 
between the parental strains, most by less than 2-fold. Using only 40 haploid segregants, 
polymorphisms between the two parental strains were used to test for linkage with 
measurements of message abundance, and permitted mapping of loci that controlled the 
differences in expression. Surprisingly, they estimated that 84% of heritability of the 
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expression differences was genetically controlled, although almost half of the mRNAs 
with expression QTLs (eQTL) in the segregating population were not detected as 
differentially expressed between the two parental strains. There was a high rate of cis-
acting alleles and a small number of trans-acting alleles that affected a disproportionate 
number of loci. Cis acting expression QTLs (eQTLs) are genes whose expression is 
controlled by variants within or near the gene itself, while trans acting eQTLs are loci 
that control gene expression of genes mapping elsewhere in the genome. Furthermore, 
eQLT for only 20% of the messages that were differentially expressed between the 
parents could be mapped, suggesting that most messages are under the genetic control of 
multiple loci. Distribution of regulatory loci was non-random; 40% of the messages fell 
into one of eight genomic regions suggesting the presence of a small number of master 
regulator loci. Clusters of co-regulated genes predominately were trans-regulated. Also, 
no functional classes were preferentially regulated by trans-factors and no enrichment of 
transcription factors was found.  
A consistent trend in the literature is an abundance of cis eQTLs, which are more 
readily identifiable because sequence variants directly impact transcription23,24. Direct 
tests of cis versus trans regulation have been performed using inter-specific hybrids in 
Drosophila25.  In this experimental system, interspecific expression differences, due to 
allelic variants in the parental and F1 hybrids, were not due to a few trans-regulators, but 
to a vast majority of dispersed cis-acting regulatory elements25. Similar studies using 
allele specific expression applied in human brain RNA showed that cis-regulated genes 
are common and may be an important source of phenotypic diversity26.  However, neither 
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of these studies directly addressed the role of trans-regulators and the interaction between 
trans and cis-regulators. 
Petretto et al. assessed cis and trans regulation across different tissues (fat, kidney, 
adrenal and left ventricle) in the BXH/HXB rat panel27.  The variation in gene expression 
levels is consistent across tissue types, as are proportions of heritable genes. Contrary to 
cis eQTLs, detection of trans eQTLs are significantly influenced by small allelic effects 
and therefore result in limited measureable change in the heritability of gene expression. 
Detection of linkage is likely lost when considered in a heterogeneous population of 
limited change particularly after the application of filtering approaches based on trait 
heritability. This biases results towards cis eQTLs and is especially evident when 
considering trans eQTL in different tissue types as it is proposed that the complex tissue 
heterogeneity also affects detection power. 
Cheung et al. used expression analysis with microarrays in humans, comparing 
both unrelated and related individuals, including siblings and twins28.  These studies 
demonstrated that expression in lymphoblastoid cells is heritable and at least partially 
under genetic control. Interestingly, they did observe a non-random distribution in the 
functional categories of genes with expression variability. Genes of cytoskeleton, protein 
modification, and transport made up one-third of the genes while those in signal 
transduction and cell death/proliferation made up less than one-fourth. 
This genetical genomics approach has been shown to be a compelling tool in the 
investigation of candidate genes associated with complex traits such as cancer 
susceptibility. The potential to develop a finite list of small effect candidate genes 
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interacting in a co-regulated fashion has been demonstrated in a number of disease 
models29-31. Since molecular pathways and networks are often coordinately regulated, 
additional searches can be performed to identify genes whose gene expression profiles 
are highly correlated with a particular candidate gene and thus may function in the same 
pathway.  Performing iterative analyses would permit the construction of hypothetical 
molecular models that could be subsequently assayed for validity and the relationship to 
the trait of interest. 
 
Transcriptional Networks 
A seminal paper that shows genetic control of transcription networks can be 
identified in multiple species (corn, mice, and humans) was published in 200324.  Results 
were combined with disease phenotypes in a segregating mouse cross to show that two 
distinct subtypes of obesity are present and controlled by different loci. These results 
demonstrated the power to partition genetically heterogeneous samples and identify 
clinical QTL controlling fat pad mass sub-groups that would otherwise be lost.  
A new form of epistatic interaction was observed in Zea mays that was not 
detectable with standard expression profiling.  Two genes with significant eQTL on 
different chromosomes appear to be uncorrelated. However, the genes appear to be 
interacting by genotype, rather by eQTL and not the genes themselves. Lastly, Schadt et 
al. used four human pedigrees to identify over 2,700 differentially expressed genes. Of 
these almost a third had a detectable genetic component. These results show causal 
  12 
relationships and allow the genetic anchoring of multiple genes under similar genetic 
control. 
Morley et al. published slightly inconsistent findings than what had previously 
been published to that date32. 3,554 genes were selected from immortalized B cell lines 
from 14 CEPH familes33 that displayed greater expression variation between individuals 
than between technical replicates. They observed cis, trans and master- regulators; 
although, most were found to act in trans (almost 78%). One –third displayed significant 
evidence of genetic linkage and trans regulation of linked genes with similar expression 
patterns. This evidence suggested that the trans factor may have a role in modulating 
chromatin domains.  
Variation in allele frequency among European and Asian cohorts caused 25% of 
the variance in expression phenotypes in lymphoblastoid cell lines34. The homozygous 
deletion of UGT2B17 was prevalent amongst the Asian derived population, and had a 
mean expression 22 times greater than those of European descent.  Additionally, different 
allelic frequencies of 11 ‘cis’ acting expression phenotypes present in both populations 
and associated with the same SNPs were influential in the differences in gene expression 
across populations. Albeit less definitive, analysis of  ‘trans’ regulators mapping to 
different genomic locations suggests that expression variation across populations may be 
due to different regulatory mechanisms.   
Considering this evidence in context with complex genetic diseases such as 
cancer susceptibility, development, and progression; disease phenotypes are due to a 
combination of allelic differences influencing transcriptional output, locally (cis), in 
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trans, through constitutional polymorphisms, modifier genes, transcriptional machinery, 
chromosomal remodeling, epigenetic control and interactions not yet conceived.  
 
Modeling Cancer-Specific Networks 
Many patients, particularly those with a family history of cancers, choose to alter 
their lifestyle or make significant health care changes when they are aware of their 
genetic predispositions. Thus, a major goal of cancer research is to identify and 
characterize cellular networks, both intracellular signaling pathways and extracellular 
cell-cell interactions, to understand the basic mechanisms, and to give informed clinical 
management of the disease. To accomplish these efforts we must generate animal models 
that mimic human cancers.    
In particular, mouse models of colorectal cancer have been highly informative 
regarding the physiological status of a tumor. Yet they are often performed on an inbred 
background, and therefore lack a major confounder that exists in the human population, 
genetic heterogeneity, and the associated impact on cancer phenotypes. A common 
progenitor within the laboratory inbred strains, Mus musculus domesticus, resulted in a 
significant decrease in genetic diversity35. We have considered the limitations of inbred 
mice strains and generated a more accurate model with increased allelic diversity that is a 
genetic, molecular, and pathological recapitulation of human sporadic colorectal cancer. 
In addition, we have applied a multidimensional modeling strategy designed to identify 
modifier genes and genetic networks associated with the susceptibility to colorectal 
cancer  
  14 
There is strain specific susceptibility to 1,2 –dimethylhydrazine (DMH) or its 
more potent metabolite intermediary azoxymethane (AOM).  Mouse exposure to AOM, a 
methylating carcinogen, results in preneoplastic aberrant crypt foci lesions that have the 
potential to develop into colon tumors in the appropriate genetic background.  These 
distally positioned tumors frequently contain mutations in the Kras2 and Ctnnb1genes 36-
39 a parallel of CRC tumors found in the descending colon of humans. Likewise, 
resistance and susceptibility predispositions are thought to be due to a combined effect of 
low penetrance genes that are difficult to detect during traditional linkage analysis 
studies.  
Spret/EiJ, of the Mus spretus species is a genetically diverse strain that is resistant 
to AOM tumor formation.  Mus musculus A/J, a sensitive frequently used laboratory 
strain, consistently develops tumors following AOM exposure. Hybrids (ASF1) of these 
strains rarely (< than 5%) develop tumors, yet backcross ((AS)A N2) progeny have a 
40% incidence of tumor induction.  The dominant resistant nature of the Spretus alleles 
provided an opportunity to identify novel susceptibility to colon cancer (Scc) modifying 
loci and tumor progression networks.  
The following 2 chapters will include the results of our efforts and application of 
similar techniques of quantitative trait mapping, expression mapping and utilizing 
molecular variation with transcript expression to narrow candidate gene selection.   
A long-term goal of this study includes performing similar experiments in 
resected tumor tissues and comparing the resulting network data with that obtained from 
the entire colon. This would enable investigators to further clarify cancer specific 
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networks, or the initiating cancer specific perturbations of normal networks, that might be 
exploited to improve therapeutic targeting, hopefully increasing efficacy of treatment 
while decreasing the undesirable morbidity currently associated with traditional 
chemotherapeutic regimens.   
An additional study is included in the fourth chapter and presents the results of an 
unintended consequence of our research efforts.  An integral part of this study includes 
the use of Mus spretus subspecies to increase genetic diversity. However, interspecific 
crosses involving M.spretus and M.musculus are frequently associated with such 
phenomena as recombination suppression and transmission distortion. We report 3 
independent occurrences of distortion, or deviation from the expected 1:1 Mendelian 
inheritance ratios. Distortion is a result of the loss of expected progeny of the depleted 
genotype and can be caused by meiotic drive, segregation distortion, or deviation from 
Mendelian Inheritance (DMI). The developmental stages during which the loss occurs, 
the location of the distortion controlling locus, and possible genetic causes of the 
distortion are investigated.  
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Abstract 
 
Colorectal cancer (CRC) is a multigenic complex disease dependent on the 
interaction of elusive genes with minimal effects.  Interactions among these genes, 
particularly those with interindividual differences make it increasingly difficult to detect 
in human genome wide association studies.  Quantitative trait mapping of sporadic CRC 
susceptibility in mice exceeds these limitations and has lead to the identification of 
cancer networks and novel low penetrance modifier genes. The present research reports 
five novel modifying loci and the interaction of low penetrance genes influencing 
susceptibility and progression of colorectal cancer.   
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 Introduction 
Colorectal cancer (CRC) is the third most commonly diagnosed form of cancer in 
the United States, and is responsible for the third largest number of cancer-related deaths 
(American Cancer Society). First-degree family members of an individual with sporadic 
cancer have a two-to-three fold increased risk of developing CRC 1,2, indicating that 
shared genetic factors likely contributed to differential susceptibility. Twin studies 
demonstrate that heritable factors account for as much as 35% of sporadic CRC cases 3.  
 Genetic analyses of both humans and mouse suggest that multiple small effect 
alleles contribute to sporadic CRC susceptibility. Recent genome-wide association 
studies in humans have identified five loci that increase risk associated with CRC4-7. In 
an independent study, three of the loci were replicated and combined analysis suggested 
that the odds ratio of a high-risk patient with two risk alleles among the three loci is at 
most 2.6 5. Similar to the variable in susceptibility to human sporadic CRC, different 
mouse strains show varying susceptibility to colonic tumors 8.  
The CRC susceptibility loci identified in mice have primarily relied upon the 
azoxymethane (AOM), or related dimethylhydrozine (DMH), carcinogen model 9-18. 
AOM primarily causes tumors in the distal mouse colon that resemble sporadic CRC of 
the descending colon in humans both histologically 19 and molecularly 20-24. Susceptibility 
to colon cancer 1 (Scc1) was one of the first low penetrance cancer modifiers to be 
successfully mapped and cloned in mice using the AOM/DMH model25.  Subsequently, 
14 additional Scc loci were reported using a recombinant congenic panel between 
BALB/cHeA and STS/A strains13-16.  Two additional colon carcinogenesis susceptibility 
loci, Ccs1 and Ccs2, were reported in studies using crosses between ICR/Ha and 
C57BL/6Ha, and between CBA/J and C57BL/6J, respectively26,27. Ccs2 and Scc7 may be 
the same locus or two different loci that both map to the telomeric end of Chromosome 
(Chr) 3.  
A recent analysis of inbred mouse strains revealed that all common laboratory 
strains have a significant contribution from Mus musculus domesticus 28. The 
consequence of common ancestry is that large genomic intervals are identical-by-descent 
(IBD) resulting in reduced diversity among common laboratory strains. Consequently, 
previous studies in mice have analyzed only part of the mouse genome for CRC 
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susceptibility loci.  SPRET/EiJ (Mus spretus) diverged from M. musculus over one 
million years ago and offers the potential to analyze additional regions of the mouse 
genome. Using genetic crosses between the AOM-resistant SPRET/EiJ strain and the 
susceptible A/J strain, we identified five additional Scc loci. Furthermore, analysis of 
interacting low penetrance susceptibility alleles was used to begin the development of a 
Scc network leading to elevated CRC susceptibility.  
 
Material and methods 
Genetic crosses 
 Female A/J (A) mice (Mus Musculus) were crossed to male SPRET/EiJ (S) mice 
(M. spretus) to generate ASF1 hybrids. Since this inter-specific cross generates infertile 
males, ASF1 females were backcrossed to A males creating a population of 238 (ASF1)A 
N2 mice. A/J and SPRET/EiJ mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). 
 
CRC phenotyping 
Mice, two-to-four months of age, were given four weekly intra-peritoneal 
injections of AOM at 10 mg/kg of body weight (Sigma-Aldrich, St. Louis, MO) as 
previously determined to optimize differential susceptibility to AOM-induced CRC 29.  
Mice were euthanized by CO2 asphyxiation 20 weeks after the last AOM dose.  A tail 
clip, liver lobe and the entire colon were dissected from each mouse.  Colons were gently 
flushed with phosphate buffer saline, mounted on a paper support, and splayed open 
along the longitudinal axis.  The number of tumors and the size and location of each 
tumor along the proximal-distal axis was recorded. 
 
Genotyping 
DNA was extracted from liver or tail samples from each mouse using Puregene 
DNA Purification Kit (Promega, Madison, WI).  Mice from the (ASF1)A N2 generation 
were genotyped using a custom Sequenom MassArray SNP Genotyping platform 
containing 182 single nucleotide polymorphisms (SNP) markers (GeneSeek, Lincoln, 
NE). The custom platform design included SNP markers from NCBI Build 37 spaced at 
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10-15 centi-Morgan (cM) intervals selected to be informative between the A and S mouse 
strains (Supplemental Table I).  
 
Statistical analysis   
Genotype probabilities were calculated using the Haldane Map algorithm in J/qtl 
software (http://research.jax.org/faculty/churchill/software/Jqtl/index.html), a Java 
interface for R/qtl 30. Since none of the tumor phenotypes could be transformed to fit a 
Gaussian distribution when all mice were included, the binary phenotype of presence or 
absence of tumors was used for the initial analysis. Binary analysis was performed by 
obtaining the maximum likelihood estimates using the EM algorithm at 2 cM intervals 
throughout the genome 31.  Mice without tumors were excluded from further quantitative 
analyses.  
Phenotypic measurements (tumor load, tumor multiplicity, average tumor 
diameter, maximum tumor diameter, and position along the proximal-distal axis) from 
samples with tumors (N = 113) were transformed using rank z-transformation parameters 
and analyzed as normally distributed phenotypes.  One dimensional genomes scans were 
performed using the EM algorithm. Tumor multiplicity could not be transformed to fit a 
normal distribution and was analyzed using an extension of the Wilcoxon Rank Sum Test 
for non-parametric interval mapping 31,32. 
 Two-dimensional analysis of tumor phenotypes was performed using Haley-Knott 
Regression algorithms to identify epistatic interactions. Significance thresholds were 
calculated by performing 1000 permutations using a marker interval of 10cM.  
 Pointwise Wilcoxon Rank sum test was performed on SNP markers in close 
proximity to previously identified Scc loci 13-16.   
 
Results  
SPRET/EiJ has a dominant colon cancer resistance locus 
When exposed to four doses of AOM, 100% of A/J mice develop colonic tumors, 
while SPRET/EiJ mice are highly resistant (Fig. 1A; 29; Bissahoyo et al, submitted). 
Genome-wide, SPRET/EiJ is dominant to the susceptible A/J as less than 5% of ASF1 
  25 
hybrids develop tumors.  Forty percent of the (ASF1)A N2 mice developed colorectal 
tumors in response to AOM exposure.  
Binary analysis of tumor presence (>1 tumor) and absence (0 tumors) detected a 
single modifier locus (LOD = 3.83; Fig. 2). This locus, designated Scc16, was most 
strongly associated with rs16808928 (Chr 11, 71cM). A tumor effect plot revealed that 
the SPRET/EiJ tumor resistance allele is dominant; mice heterozygous at rs16808928 
have an increased likelihood of being tumor free than mice homozygous for the A/J allele 
(t test, p < 0.0001). Two-dimensional analysis also revealed a suggestive interaction 
between Scc16 and a pseudomarker located on Chr 6 at 13cM near the previously 
reported Scc13 locus 13.  
 Pointwise analysis was performed using SNP markers in close proximity to 
previously identified Scc and Ccs loci 13,15,16,26,27,33. Although markers near Scc9, Scc11, 
Scc13 and Scc15 were significantly associated with tumor presence, none reached 
significance threshold (p=0.05) established for genome-wide analysis (Table 1) 13,16.  
 
Colorectal cancer phenotypes are determined by oligogenic modifier loci  
Mice without tumors were excluded from analysis of tumor multiplicity, tumor 
load, tumor diameter, maximum tumor diameter, and position along the colon (Fig. 1B). 
Many tumor phenotypes were correlated within the (ASF1)A N2 population (Fig. 1C). 
Tumor multiplicity (number of tumors per mouse) is the only phenotype that was not 
transformed into a normal distribution. Non-parametric methods detected a single 
modifier on Chr 8, named Scc17, (rs13479769, 30cM; LOD = 2.66; Table 2) explaining 
10.1% (p = 0.001) of the variance in tumor number. An effect plot reveals that mice 
heterozygous at the Scc17 locus have fewer tumors than mice homozygous for the A/J 
allele (t test, p= 0.0003), showing that the SPRET/EiJ allele dominantly reduces tumor 
multiplicity. An additional putative tumor multiplicity modifier on Chr 1 (rs3658044, 
Scc18) was slightly below the suggestive threshold; this locus explains 7.6% (p = 0.003) 
of the phenotypic variance. 
Analysis of tumor load (tumor diameter x tumor number) also identified one 
modifier, which explained 11.4% (p > 0.0001) of the variance. Scc19 was most strongly 
associated with rs16805672 on Chr 6 at 37 cM (LOD of 2.826; p > 0.05). A suggestive 
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sex-dependent modifier locus on Chr 14 (Scc20) was detected for maximum tumor size. 
Scc20 explained less than 1% (p = 0.325) of the variance, below the threshold for 
significance (p> 0.05; LOD = 3.421). No loci were detected that modified mean tumor 
diameter or maximum tumor diameter.   
The colon has a proximal-distal axis with regional differences in cell composition 
and function.  Modifiers influencing tumor positioning along the distal axis have not been 
previously reported. To identify whether the position of tumors and the number of tumors 
within the colon were interacting phenotypes, they were considered as covariates in a 
one-dimensional scan. One modifier was identified on Chr 1 maximally associated with 
rs8238935 at 32 cM (LOD 4.067; Fig. 5). This locus is slightly proximal to Scc18 but the 
overlap in confidence intervals suggests they may be the same.  Mice homozygous for 
A/J alleles are likely to have a greater number of tumors that are positioned more distally 
than mice heterozygous at Scc18.   
 
Epistatic interactions among modifiers 
Two-dimensional modifier scans were performed on all phenotypes to detect 
allele combinations that may have gone undetected using one-dimensional scans. 
Analysis of tumor load revealed one significant (α = 0.05) and one suggestive interaction 
(α = 0.1; Fig. 3, Table 2). The significant interaction was detected between Chr 8 (Scc17) 
and a locus on Chr 1 (possibly Scc18) that did not reach significance in a one-
dimensional scan (Full LOD = 5.667, p = 0.046 and Additive LOD = 4.486, p = 0.043). 
The second interaction was detected between Scc19 and a locus that lies adjacent to 
Scc18 (peak at rs16810780; Full LOD = 5.373, p = 0.073 and Additive LOD = 4.936, p = 
0.016) Marker rs3658044, which defines Scc18, is approximately 10 cM proximal to 
rs16810780. Effect plots of tumor load interaction shows that the presence of the 
SPRET/EiJ allele at either locus results in small phenotypic differences. However, mice 
that are homozygous for the A/J allele at both loci bear a significantly larger tumor load 
(Fig. 4). 
In a test similar to the one-dimensional scan, the effects of sex as a covariate on 
tumor load detected a suggestive interaction between Scc19 and Scc20 (Full LOD = 
6.025, p = 0.575 and Additive LOD = 5.987, p = 0.066; Fig. 4).  
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The interaction LOD between Scc18 and a locus on chromosome 10 is 6.580 (Full 
– Add). This locus is defined by a pseudomarker at 53 cM and is within the 17.5 cM 
confidence interval of the previously reported Scc9 16 (Table 1).  
 
Discussion 
Several loci influencing CRC susceptibility have been identified in crosses 
between resistant and susceptible mouse strains.  Previous studies using recombinant 
congenic strains led to the identification of 15 Scc loci, with almost half being involved in 
two-way interactions 13-16,33. Analysis of additional crosses was used to identify Ccs1 and 
Ccs2 15,26,27.  We employed an inter-specific backcross to identify five additional loci, 
Scc16-20. Four of these loci were found to modify tumor progression and phenotypic 
outcome. Interactions between these modifiers are suggestive of a CRC progression 
network. Although Scc16 was the only modifier of susceptibility identified in a genome 
wide scan, additional modifiers were identified by pointwise analysis of the Scc loci.  
These small effect modifiers highlight the significance and difficulties involved in 
identifying allelic combinations that influence cancer progression.   
Genome-wide analysis of an inter-specific backcross between SPRETEiJ and A/J 
detected one locus with strong effect controlling AOM-induced tumor susceptibility 
called Scc16. Previous low penetrance susceptibility modifiers Scc9, 11, 13 and 15 were 
only detected in this cross using a pointwise analysis (Fig. 6). Although Scc13 and 15 
were previously detected by pairwise interactions, only Scc13 had a suggested interaction 
with Scc16.  Scc13 was also found to interact with Scc14 and more importantly Scc1, 
suggesting a role as a modifying locus that confers added resistance. Scc16 provided an 
example of the strength of the dominance of tumor resistance of SPRET/EiJ.  
Interactions between loci and phenotypes suggest colon cancer modifiers may 
function within genetic and phenotypic networks. Tumor load is most strongly influenced 
by Scc19 located on Chr 6. Furthermore, Scc17 and 18, modulating tumor number, were 
found to interact to affect tumor load. Tumor load is also regulated in a sex-dependent 
fashion by Scc20, which was detected using maximum tumor diameter. Also, multiple 
pathways driving tumor growth appear to converge at Scc18 and, to a lesser extent, 
Scc19.  
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Despite inheritance from the dominant resistant strain, Scc19 is associated with an 
increased tumor load. Scc18 appears to weakly interact with Scc19, yet this locus or in 
combination with another unidentified locus has the ability to cause a decrease in tumor 
burden. This demonstrates that both strains harbor recessive carcinogenic alleles that are 
only evident with the introduction of new allele combinations.  
Modifiers also appear to influence the relative position of tumors within the 
colon. Scc18 on Chr 1 a suggestive modifier of tumor number, significantly modifies 
spatial positioning.  Scc9, which appears to interact with Scc18, is located in a region 
with conserved synteny to human Chr 12. Interestingly, there are a number of reports of 
hypermethylation, overexpression, and chromosomal loss of genes associated with colon 
cancer in 12q34-36. The detection of this locus within our study increases the possibility 
that Scc9 represents an allele that may be associated with susceptibility in the human 
population. 
A number of genome-wide association studies have been conducted in patients, 
which revealed several common variants that function as low penetrance susceptibility 
alleles.  Although none of the mouse susceptibility loci that have been identified are 
concordant with human studies, these loci may function in similar pathways or may have 
stronger effects in different patient populations. Future identification of the underlying 
genes responsible for the Scc loci should reveal the relationship between mouse and 
human CRC susceptibility and how different modifiers can influence traits like presence 
of tumors or their location along the colon.   
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Table 1. Pointwise analysis of novel and previously mapped colon cancer susceptibility 
loci.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     * denotes loci identified in this work. 
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Table 2. Colon cancer modifer loci identified in an (ASF1)A N2 backcross. Linkage 
threshold were determined by permutation testing. P-value < 0.05, significant. P-value < 
0.1, suggestive.  
 
 
 
Sample size of N=110, with exception +N= 238. 
* denotes modifier loci that reach the suggestive threshold.  
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Figure 1A. Distribution of tumor penetrance within the parental, F1 hetorozygous and 
backcross mice.  B. Plots of tumor phenotypes in tumor-bearing mice. 
 
A.   
 
 
 
 
 
 
 
 
 
 
B.
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Figure 1C. Correlation matrix of tumor phenotypes. 
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Figure 2. Genome scan for modifier loci controlling the binary tumor susceptibility 
phenotype. Inset, effect plot of the peak marker. 
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Figure 3. Heat plot of two-dimensional modifier scan for select chromosomes. 
Interactions were found for loci on Chrs 1 x 6 (Scc18 x Scc19), 1 x 8 (Scc17 x Scc18), 
and 6 x 14 (Scc19 x Scc20).  
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Figure 4. Effect plots of loci influencing tumor load. 
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Figure 5. Genome scan for tumor position.  
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Figure 6. Comparative locations of all reported colon cancer susceptibility loci. Novel 
loci identified in this work are highlighted in red.  
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Abstract 
Transcript expression and abundance can be used as an endo-phenotype to 
mechanistically link variation at the genetic level with phenotypic differences.  The 
molecular networks underlying complex traits like cancer susceptibility remaines a 
meshwork of genetic interactions with limited access to the architectural blueprints.  
Technological advances have propelled expression quantitative trait mapping to the 
scientific forefront as a credible methodology that extends our understanding of cancer 
biology. We applied transcript mapping to a mouse model of sporadic colorectal cancer 
to create susceptibility network that includes candidate gene hubs, pleiomorphic variants, 
and genetic interactions. Coordinately regulated transcripts were clustered into modules 
enriched for genes mediating cell cycle regulation and cancer progression. With these 
efforts we seek to provide additional clarity about genetic networks influencing colon 
cancer susceptibility.   
  44 
Introduction 
Colorectal cancer (CRC) is not caused by a single gene but multiple perturbations 
within a complex network that drives disease susceptibility and progression. Expression 
mapping, the process of linking transcript expression levels to causal genetic 
polymorphisms, offers an effective method to identify the molecular pathways and 
candidate genes that contribute to differential cancer susceptibility1-4.  
In humans and mouse models genome-wide association studies and transcriptome 
mapping has begun to provide clarity to the complexities of multigeneic phenotypes and 
diseases. The utility of mouse models of complex disease is of great importance as large 
genome-wide association studies, although successful, have limited ability to provide 
molecular insights required to understand the function of SNPs with small effects. This is 
especially significant as it is reported that half of the yeast quantitative traits are the 
results of five or more additive effects, which are also possibly context and environment 
dependent5.  
Recent studies of complex disease have led to the implication of candidate genes 
with a functional role in disease progression. However, confirming these genes with 
experimental data supports that these methods are accurately identifying genes conferring 
disease susceptibility. ERB3 was presumed to have a role in type 1 diabetes (T1D) 
susceptibility6. However, its expression does not correlate with T1D associated SNPs 
found during a genome wide association study6. The expression of RPS26, an adjacent 
gene explained 40% of the gene expression variation, thus confirming its ability to confer 
susceptibility to T1D. The glycolosis pathway was found to modify AKT1 regulated 
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proliferation in murine prostate7. These findings were validated in three independent 
human data sets. Where human validation is not readily accessible, studies of complex 
disease transcript mapping reveals list of candidate genes that are not simply random 
unassociated groupings.  They are comprised of correlated transcripts that contribute to 
pathway construction 8-10.  
Previously, we performed a genome-wide linkage analysis leading to the 
detection of five new susceptibility to colorectal cancer loci (Scc16-20) using an 
interspecific backcross between Mus spretus (SPRET/EiJ) and M. musculus (A/J). The 
selected inbred strains are from distinct species, and thus have a much higher amount of 
naturally occurring polymorphisms than is found in classical inbred strains11. 
Carcinogenesis studies involving M. spretus have found that this species is generally 
resistant to tumor susceptibility; furthermore, F1 hybrids with classical inbred strains are 
similar to the M. spretus parent9,11-13.  N2 backcross progeny display an intermediate 
phenotype; as in this study, approximately 40% of the mice display tumors.  
A multitude of causal SNP variants have been shown to exert mechanistic control 
in expression mapping of complex phenotypes1,14-16. Therefore co-regulated genes within 
a network should display correlated transcript abundance. Individual genes may not 
always display significant expression changes associated with a phenotype under study 
but rather the gene transcripts should correlate to suggest a conserved network that, as a 
whole, is tied to the phenotypic outcome. We report the application of two approaches: 1. 
isolating prospective candidate genes in a previously identified tumor susceptibility 
network and 2. identifying transcriptional networks associated with differential colon 
cancer susceptibility.   
  46 
Methods 
Mouse generation and phenotyping. Female A/J (A) representing M. musculus and 
male SPRET/EiJ (S) representing M. spretus were crossed to generate interspecific 
hybrids (ASF1). Only female ASF1 hybrids were backcrossed to A/J males since ASF1 
males are infertile. A population of 144 (AS)AN2 mice were treated with azoxymethane 
(AOM) (Sigma-Aldrich, St.Louis, MO). At two to four months of age, mice received four 
weekly intra-peritoneal injections of AOM at 10mg/kg body weight. Mice were 
euthanized by CO2 asphyxiation 20 weeks after the final AOM treatment. Colons were 
removed, gently flushed with phosphate buffer saline, mounted on a paper support, and 
splayed open along the longitudinal axis.  Tumor number, diameter, and location along 
the proximal-distal axis were recorded. Whole colons without tumors were snap frozen in 
liquid nitrogen following tumor resection.  
Genotyping. DNA was extracted from liver or tail samples from each mouse using the 
Puregene DNA Purification Kit (Promega, Madison, WI).  DNA from mice of the 
(AS)AN2 generation were commercially genotyped (Illumina, Sand Diego, CA and 
Geneseek, Lincoln, NE). 439 SNP markers spaced at 10-15 centi-Morgan (cM) intervals 
were used (NCBI Build 37; Supplementary Table).  
Microarray analyses. RNA was isolated from pulverized frozen colon tissue using 
TRIzol (Invitrogen, Carlsbad, CA), and amplified using the Illumina® TotalPrep RNA 
Amplification kit (Ambion, Austin, TX). 1.5 µg of biotinylated cRNA was hybridized to 
the Illumina Mouse 6 Sentrix array (version 1, Illumina, San Diego, CA) overnight at 
55oC. Following hybridization, the arrays were serially washed in Illumina Buffers (High 
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Temperature Wash Buffer, 10 min; E1BC Buffer, 5 min; 100% ethanol, 10 min; E1BC 
Buffer, 2 min) and coated with streptavidin-Cy3 (1 mg/mL in Block E1 Buffer, Illumina). 
Excess stain was removed in a final E1BC Buffer wash, arrays were dried, and probe 
intensity recorded using the Illumina Bead Array confocal laser scanner. 
Gene transcript processing and statistical analyses. Lumi, an R based software for 
Illumina expression, was used to log transform and normalize ~ 46,000 transcripts 17. 
Loess and Quantile methods were applied, and the data was filtered at an Illumina 
detection score of 0.95 and above. Significant differential gene expression was examined 
for tumor susceptibility using Statistical Analysis of Microarrays (SAM) software. Two 
class unpaired (with and without tumors) analysis were run with 1000 permutations at a 
false discovery rate (FDR) ≤ 5%18.   
Expression QTL mapping . FASTMAP was used to map regulators of differentially 
expressed transcripts 19.  This mapping algorithm organizes SNPs into a Hamming 
distance based tree to minimize the calculation time required to measure the association 
between genotype and transcript expression19. The significance threshold was set to p = 
0.90 using 1000 permuted iterations. An FDR q = 0.03 was applied to each transcript. 
Images were generated using R graphing tools. 
Modulated Modularity Clustering (MMC). MMC is a clustering algorithm that allows 
network inferences to be made from gene expression profiles. Genetically correlated 
transcripts were partitioned into modules that are similar within a grouping and dissimilar 
outside of groups 20,21,22. An r-value of genetic correlation within each module is 
reported.  
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Results 
We theorized that abundant SNP variants within M.spretus strain would result in unequal 
hybridization to Illumina probe sequences23,24. Probes were designed to target the 
C57BL/6J genome, which is genetically similar to A/J and differs from SPRET/EiJ by on 
average one SNP every 50 base pairs. If hybridization selectivity does not occur, allele 
specific expression should be equal among transcripts whose expression is modulated by 
a variant within its gene. Because SNP markers used were not evenly spaced throughout 
the genome, cis eQTL were defined by a genes proximity to its closest SNP. We 
observed lower expression of SPRET/EiJ alleles in N2 progeny among cis eQTL (using q 
= 0.03; Fig. 3C). In addition, the expression of control samples (A/J, SPRET/EiJ, ASF1) 
showed an intermediate ASF1 expression, with lower SPRET/EiJ expression.  
Candidate Gene Selection. Four novel quantitative trait loci influencing tumor number 
(Scc17, Scc18), tumor load (Scc19), maximum tumor diameter (Scc20), and position 
along the colon (Scc18) were connected in tumor bearing susceptible mice. Putative 
candidate genes were selected amongst transcripts whose expression patterns most 
correlated with the SNP markers underlying the confidence intervals of each Scc locus.  
Scc17 had the largest confidence interval (∼58Mb) with the most genes (233). Yet, only 
8.5% of genes showed a high degree of correlation (Pearson’s correlation ≥ |0.5|) (Fig. 
1A). Similar percent correlation was observed in all loci, Scc18, 5.9%; Scc19, 6.06%; 
Scc20, 8.47% resulting in 34 total candidate genes.  
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Functional Analysis of Tumor Growth Promoting Network 
 Putative candidate genes were imported into Ingenuity Pathway Analysis (IPA) 
for ontological querying and pathway analysis using the curated Ingenuity Pathway 
Knowledge Base. The top network contained 11 candidate molecules including the 
oncogene Jun and Mapk1. Mef2B (Scc17), Ptpn18 (Scc18), Tax1bp1 (Scc19), Ecd 
(Scc20); molecules representing each Scc locus were found to interact with Hnf4α, an 
integral gene in liver, kidney and intestine development (Fig. 2)25. Hnf4α may influence 
inter-individual gene expression differences amongst these genes influencing tumor 
phenotypes 26.  
Loci on Chr 4 and 11 Modulating CRC Susceptibility.  Fastmap software was used to 
identify and associate genomic locations regulating transcript expression. Trans bands 
controlling colon gene expression were identified on Chrs 4, 5, 8, 11 and 17 (Fig. 3). 
Additionally, eQTLs clustered in regions known to influence tumor susceptibility (Scc11, 
Chr 4; Scc15, Scc16, Chr 11) (Fig. 3). Two class unpaired differential expression analysis 
were performed on all cis and trans genes that mapped to the QTL cluster and 
susceptibility modifying loci. Differentially expressed genes were enriched with 
molecules involved in cancer, specifically Scc11 that was associated with a network 
containing cell cycle genes and Scc15/16 that were associated with a network containing 
genes influential in cellular growth. Ingenuity Pathway Analysis was limited to direct 
interactions in putative susceptibility network creations as numerous genes were 
included. The top network for Scc11 contains genes that interact with Src, Pparg and 
Stat1 (Fig. 4). The top network of Scc15/16 contains several genes with roles in cancer 
progression such as Prkcα and Pttg1 (Fig. 5).  
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MMC Directed Susceptibility Network Identification. MMC analysis on the 12,725 
differentially expressed genes in the (AS)AN2 progeny revealed 800 modules clustered 
by similarity in transcript abundance and expression (Fig. 6). Transcript variance resulted 
in modules of all sizes.  Module 651 had an absolute intermodule correlation of 0.46337 
and was among the largest with 647 transcripts. Module 328 is also of considerable size 
and contains 232 transcripts with an |r|= 0.56848. These modules suggestively represent 
multiple networks or co-regulated transcripts within a network.  
 To identify additional colon cancer specific networks, we compared MMC 
groupings with SAM results. Approximately 1,200 genes were differentially expressed 
(FDR = 4.65%) between mice that had tumors and those that did not. Among the tumor 
susceptibility influenced genes, the most abundant modules contained genes with 
functional relationships to cancer, inflammation, cell signaling, growth, and proliferation 
(Fig. 7, 8). Large modules were not always enriched in tumor susceptibility gene lists, 
thus confirming a common biological function influencing module grouping.  Transcripts 
of the most represented modules were imported into IPA to recreate potential cancer 
networks.   
Discussion 
Genetic regulation of transcript expression is tissue specific and genetic 
background dependent14,27,28. We selected SPRET/EiJ, a distinct mouse species in order to 
capture greater genetic heterogeneity. As expected, differences due to the strain specific 
hybridization selectivity and expression were observed. Although the genome-wide 
expression differences between the strains are significant, the expression differences at 
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individual probes appear minimal. MMC analysis performed on all normalized transcripts 
demonstrates a high degree of correlation across all modules (Fig. 6). As a result, MMC 
analysis was able to successfully group correlated transcripts into biologically relevant 
modules. Strongly disregulated genes due to M.  spretus and M. musculus sequence 
divergence are not likely to be included following SAM analysis. Therefore our analysis 
and network generation can be performed with susceptibility associated expression 
phenotypes influenced by genetic variation.  
Transcript expression driven by genomic variants was used to create a tumor 
progression network and several interacting Scc networks. Results from a previous study 
on CRC cancer modifiers were used to narrow candidate gene selection, and transcription 
clusters were found to overlap with three Scc loci (Scc11, Scc15, and Scc16) (Eversley; 
submitted). In addition, MMC analysis was used to guide efforts by clustering transcripts 
into biologically meaningful modules. 
We previously identified four interacting loci that influence tumor progression in 
a susceptible host. By correlating transcript expression with genotype, we were able to 
select candidate genes and narrow the list using an IPA generated network (Fig. 2). We 
proposed that HNF4α isoforms contain allelic variants that cause disregulation in 
interacting genes Ptpn18, Mef2b, Tax1bp1, and Ecd, thus promoting tumor progression. 
Recent reports suggest that HNF4α inhibition suppresses growth in CRC cell lines and 
xenotransplanted mice29. Additionally, Hnf4α was shown to be a factor influencing inter-
individual variation in hepatic isoforms that influence cancer susceptibility26.  Mef2b, 
myocyte enhancing factor 2, is a DNA dependent regulator of transcription particularly 
found in muscle specific genes 30-32.  Mef2b  interacts with other transcription factors to 
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regulate cell cycle progression through promoter induction of the oncogene JUN 31,32.  
PTPN18, once thought to be a tumor suppressor due to its regulation of ERBB2 in breast 
cancer, may also have a nonfunctional isoform that negatively regulates cell proliferation 
33,34. Interestingly Tax1bp1 has been implicated in A20 protein complex necessary for the 
termination of NFKappaB and Jnk signaling. Transcription factor Ecd (Gcr2, Hsgt1) and 
its role in glycolytic enzyme activity has been characterized in Saccharomyces cerevisiae 
but has not been linked to cancer. However, a plausible link exists as cancer cells exhibit 
increased glycolysis and ATP generation through metabolic pathway is essential for all 
cells.  
Figure 3B shows transcript expression that is locally regulated or cis acting, and 
strong trans bands mapping to distant chromosomes. Loci on Chr 4 and 11 contain a 
number of trans-QTL that coincides with Scc loci.  Scc15 and Scc16 represent adjacent 
genes on Chr 11. These overlapping networks were combined to avoid separating a 
region of strong transcriptional control. The transcriptional pathway generated centers 
around three interacting cis-genes, Pkcα, Gnb2l1 (Rack1), and Stat1 (Fig. 5). Scc15/16 
genes directly modulate genes central to the Scc11 associated network. Cells depleted of 
RACK1 (GNB2L1) display accelerated growth no longer suppressing SRC at the G1 
checkpoint35 (Fig. 4). This is particularly noteworthy because disruption of Src activity 
represents an early developmental change in colon tissue.  Gnb2l1 also binds with several 
other colon cancer related genes Erk and Egfr.  
 The Chr 4 transcription cluster does not appear to be controlled by genes involved 
in cancer progression. The preponderance of genes imported into IPA were involved in 
cancer, cell growth, and proliferation yet they do not interact, directly or indirectly. Cis 
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and trans regulated transcripts mapping to this locus seem to be modified by distally 
located genes.  Tgfβ1 is physically located on Chr 7 yet regulated by a gene on Chr 4 that 
is uninvolved in cancer progression.  This may represent an interaction  with a 
SPRET/EiJ inherited allele that influences cancer susceptibility.  
 Modulated Modularity Clustering is a functional genomics tool, whose utility was 
demonstrated in inbred Drosophila melanogaster and human lymphocytes 20-22. High 
correlation among transcripts can be used to group differentially expressed transcripts 
into biologically meaningful modules representing co-regulated gene networks. This 
method was applied to our mouse colon RNA expression data set and revealed clusters of 
interconnected genes that were enriched in functional categories involved in cancer, 
gastrointestinal disease, inflammatory response, vitamin and mineral absorption, and cell 
cycle progression. We assessed the ability to detect modules associated with cancer 
progression following SAM analysis on genes associated with tumor susceptibility. Two 
of the larger modules were selected for closer inspection and discussion due to the 
likelihood of revealing a larger interactome network.  Module 443 is enriched for genes 
involved in inflammatory response and antigen presentation (Fig.8). Prolonged 
inflammation (Inflammatory bowel disease) or chronic irritation such as Helicobacter 
pylori colonization, is more frequently associated with colon cancer predisposition.  
Combined MMC and SAM analysis revealed an additional link between 
metabolic pathway variants and cancer, as almost half of the transcripts in module 615 
were associated with cancer molecules. Transcripts in this module are also involved in 
the canonical pathways of metabolism (xenobiotic metabolism by cytrochrome p450, 
citrate cycle, and glutathione metabolism) (Fig.7). It is expected to find metabolic 
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regulation in colon tissue, the source of nutrient intake. However, metabolic genes, such 
as GSTM1, included among differentially regulated tumor susceptible genes and under 
similar transcriptional regulation as cancer cells are unexpected. Interestingly, 
polymorphisms in GSTP1, GSTM1, and GSTT1 have been associated with increased risk 
of breast, lung, bladder, and colon cancer 36-38. Genetic polymorphisms within xenobiotic 
targeted pathways would potentially present a risk factor that could not be avoided even 
with dietary modifications. This network posits putative transcription regulators 
interacting with downstream susceptibility modifiers and increases our understanding of 
cancer susceptibility networks.  
 We have demonstrated the utility of combining transcript abundance with 
genomic information to gain a greater understanding of colon cancer.  Additional work is 
required to confirm these potential candidate genes and interaction networks; yet, we are 
hopeful the results will be help in human CRC susceptibility.   
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Figure 1. Histogram of candidate genes with highest correlation between genotype and 
transcript expression. r ≥ |0.5|.  Red lines define r = |0.5|.  
 
 
 
 
 
 
 
 
 
 
 
  56 
Figure 2. Interaction network of putative Scc candidate genes.  
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Figure 3A. Genome wide clustering of transcript expression control.  
eQTL with LRS 0.3 or greater are displayed as colored transcripts.  
 
 
 
  58 
Figure 3B. Transcriptome Map 
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Figure 3C. Strain specific expression of cis-eQTL. 
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Figure 4. Colon cancer susceptibility network on chromosome 4 near Scc11. 
 
 
Genes highlighted in red distinguish molecules submitted to IPA for functional analysis, 
and genes supplied by the IPA knowledge base. 
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Figure 5. Colon cancer susceptibility network on chromosome 11 near Scc15 and Scc16. 
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Figure 6. Modulated Modularity Clustering (MMC) of the 12,725 transcripts into 800 
modules.  Red squares on the diagonal axis of the correlation matrix represent modules of 
correlated transcripts. 
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Figure 7. MMC guided Network Creation. Inflammatory Response (Module 443) 
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Figure 8. MMC guided Network Creation. Cancer susceptibility and Metabolism 
(molecules in red) (Module 651).  
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ABSTRACT 
Segregation distortion is a common occurrence within interspecific mouse 
crosses.  We report three independent events of deviation from the expected 50:50 
Mendelian inheritance ratios on chromosome 7, 10, and 11.  The mechanistic causes for 
these events are unknown but are likely due to post-natal growth and developmental 
delays.  The probable locations of the distortion controlling loci have been calculated but 
the genetic identity has yet to be determined. 
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INTRODUCTION 
Commonly used inbred mouse strains, which trace their genetic ancestry 
primarily to Mus musculus domesticus 1, have extensive interspecific polymorphic 
differences when compared to M. spretus. Mus spretus is frequently used for interspecific 
crosses because female hybrids are fertile and contain a large number of polymorphisms 
distributed across the entire genome 2.  However, backcrosses using interspecific hybrids 
often result in skewed distributions in the inheritance of polymorphic alleles, a 
phenomena called transmission ratio distortion (TRD) 3-8. Transmission ratio distortion is 
defined as statistically significant deviation from the expected 1:1 Mendelian ratios of 
allele inheritance, resulting in a reduction of the expected progeny of a given genotype.  
M. spretus derived TRD was identified during linkage testing on chromosomes 2, 4, and 
10 3,9-11. Montagutelli et al, described the first efforts to map the causative loci 
influencing TRD in four backcrosses involving M.spretus 8.  This event is not limited to 
the Spretus sub-species and has been observed in remote Mus musculus populations on 
chromosome 1 and commonly derived strains on chromosome 11 12-14. The causes of this 
TRD can be meiotic drive, segregation distortion (SD), or deviation from Mendelian 
inheritance (DMI) 8.  
The defining characteristic of meiotic drive is that TRD occurs during meiosis.  
Consequently, the resulting gametes are not lost and fertility is unaffected, but the 
inheritance of adjacent neutral polymorphisms is affected 15,16. Meitoic drive is one of the 
more common examples in which a “selfish gene” drives the preferential selection and 
fertilization of an oocyte 8,15. An example of meiotic drive at the second meiotic division 
can be seen in the DDK syndrome at the Om locus on mouse Chromosome (Chr) 11 17,18.   
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Segregation distortion is due to a chromosomal transmission imbalance during 
meiosis.  This differential effect can also occur post meiosis but prior to fertilization as 
occurs in Droshophila melanogaster and the mouse t-haplotype 19-23.  Conversely, DMI 
occurs as a result of post-meiotic lethality of embryos or neonates with a particular 
genotype.   
In this study we report three independent occurrences of TRD caused by post-
meiotic lethality in an interspecific backcross population of Mus spretus and Mus 
musculus. A preferential selection of A/J alleles is observed on chromosome 7 and 
M.spretus alleles are evident on chromosome 10 and 11, In addition, Chr 11 DMI is 
influenced by a locus on Chr 3.  
MATERIALS AND METHODS 
Genetic crosses: All mice were obtained from the Jackson laboratory (Bar 
Harbor, ME). Female M. musculus mice of the A/J (A) strain were crossed to male M. 
spretus of the SPRET/EiJ (S) strain to generate interspecific hybrids. Female ASF1 
hybrids were backcrossed to A/J males to generate a segregating population of 238 
(AS)AN2 mice to map colon cancer susceptibility loci (Eversley, submitted). Mice were 
euthanized at 6 months of age and DNA extracted from tail and liver tissue using a 
Purgene DNA Extraction kit (Promega, Madison, WI). 
Additional cohorts of (AS)AN2 offspring were generated and euthanized within 
two days of birth (N = 88),or prenatally at mid-gestation between 12.5 – 19.5 days post-
coitus (N = 60). For prenatal samples, placenta and embryo weights were recorded and 
DNA was extracted from tail tissue by phenol-chloroform extraction. 
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Genotyping: DNA from (AS)AN2 mice was commercially genotyped using 254 
informative single nucleotide polymorphisms (SNP) markers (Illumina, San Diego, CA). 
Additional genotyping was done using a custom Sequenom MassArray SNP Genotyping 
platform containing 182 single nucleotide polymorphisms (SNP) markers (Geneseek, 
Lincoln, NE). Sequenom SNP markers were selected from NCBI Build 37 placed at 
approximately 10-15cM intervals and have been previously described (Eversley, 
submitted).  
The following microsatellite markers were used to test for TRD in embryos and 
neonates: D7Mit309, D10Mit145, D10Mit108, D11Mit338, D11Mit152, and D11Mit225 
(Operon Biotechnologies, Huntsville, AL). Standard PCR methods were used 24,25. PCR 
products were fractionated using 2%-4% agarose gels and stained with ethidium bromide 
for visualization.   
 Statistical analysis: Evaluation of loci for TRD was performed on each cross 
using Chi square analysis with one degree of freedom. A corrected version of 
Montagutelli’s goodness of fit test for a single distorted locus was previously described 
8,26. Correlation analysis was performed to determine an association between genotype 
and placental mass or birth weight.  
 
RESULTS 
Analysis of genotyping data from an interspecific backcross established to map 
colon cancer susceptibility modifiers (Eversley, submitted) revealed the occurrence of 
three genomic intervals with non-Mendelian inheritance patterns. The number of progeny 
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from an ASF1 dam inheriting SPRET/EiJ or A/J alleles at each SNP was used as a 
measurement of distortion frequency. A TRD favoring A/J alleles (66%) was observed on 
Chr 7  (X2 = 15.11; P < 1.01 X 10-4; Fig.1). Elevated frequencies of SPRET/EiJ alleles 
(71% and 68%) were observed on Chr 10 (X2 = 25.04; P < 5.61 X 10-7; Fig. 2) and Chr 11 
(and X2 = 17.86; P < 2.38 X 10-5; Fig. 3, Table 1). There was no difference in TRD 
between female or male progeny (data not shown). Although mortality rates between 
birth and 2 months of age, when mice were induced to develop colon cancer, were not 
recorded, post-weaning loss was minimal and could not account for the absence of alleles 
in the TRD intervals. These data suggest that allele loss leading to TRD occurs before 
weaning. 
To determine the timing of allele loss, (AS)AN2 neonates (N = 88) and embryos 
(N = 60)  were generated. Mendelian ratios were observed in embryos and in neonates for 
each of the three TRD intervals (Table 2). These data show that the TRD is not a result of 
a meiotic selection in the ASF1 heterozygous dam, nor due to preferential survival of 
embryos.  In addition, there was not a significant connection between birth weight, 
placental mass, and genotype. We therefore conclude that the TRD occurs postnatally but 
before two months of age.   
We used a corrected formula 26, originally reported by Montagutelli et al to detect 
single or multiple TRD loci 8,26, to identify a single locus of minimum goodness of fit for 
each TRD loci on Chr 7, 10, and 11.  The causative locus of distortion on Chr 7 was 
narrowed to a 6 cM interval near 27.8 cM. We were able to position the best goodness of 
fit (GF) location by incremental shifting to 0.2 cM away from rs8260829 at 28 cM (GF = 
10.003, 31 d.f., not significant P = 0.99). (Fig.1) 
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  Among 19 SNPs on Chr 10 a single peak is evident at rs4228380 (Fig. 2).  Our 
model posits that a single distorter is located at 48.5cM with expected distortion of 71%.  
This is in good agreement with the predictions of the GF model with GF = 12.08, 19 d.f., 
not significant p = 0.88. Incremental adjustments of the location and TRD have no affect 
on the minimum GF.   
  A broad maximum peak of 67% TRD extends approximately 8cM along Chr 11, 
which contains 16 SNPs incrementally spaced with a maximum interval of 9 cM. After 
adjusting the location of GF and TRD, we found the minimum GF to be near rs13481119, 
45 cM away from the centromere (GF = 3.631, 16 d.f., not significant P = 0.99). 
Transmission of the SPRET/EiJ alleles in this region is strongly influenced by co-
segregating SPRET/EiJ alleles on Chr 3. (Table1). The strongest epistatic interaction 
occurs between a locus approximately 4.6 cM away from the centromere on Chr 3 and at 
46cM on Chr 11 (X2 = 11.8851, P = 0.000566; Table 1). 
 
DISCUSSION 
 DMI has been reported as a frequent consequence of interspecific backcrosses. 
We have identified 3 independent loci causing strong distortion skewed toward 
SPRET/Ei alleles on Chr 10 and 11 and favoring A/J alleles on Chr. 7. Although we 
report the third instance of distortion in  Chr11, neither of the previous studies documents 
an interaction with the proximal portion of Chr 3. The distorting losses all occur prior to 
weaning and are likely the result of allelic incompatibilities or due to strain specific 
differences. 
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The region of maximum distortion on Chr 7 has been reported to be replete with 
imprinted genes influencing fetal and placental growth, postnatal growth, lethality and 
viability. Most notably, this region contains the imprinted gene cluster involved in the 
nuerological disorders Prader-Willi Syndrome (PWS) and Angelman Syndrome (AS). 
PWS is caused by the lack of the paternal copy or maternal imprinting, while AS is 
caused by a lack of maternal expression due to deleted genes or paternal imprinting 27. 
Investigation into the genes underlying PWS reveals that Necdin mutants display 
respiratory instability and die within the first week after birth 28. 45% of mice with 
maternally transmitted AS die seven days after birth or  display a reduction in post natal 
growth, and viability 29,30.  
It is more plausible that distortion evident in this study was due to maternally 
inherited chromosomes with a paternal imprint. Angelman Syndrom, rather than PWS, is 
caused by a loss of maternal genetic contribution. Distortion favors A/J homozygosity 
(66%) in the (AS)AN2 backcross. Although, PWS causes postnatal lethality, the 
phenotype of AS is not 100% penetrant and more accurately explains the abundance of 
homozygous animals in our cross. We also genotyped pre-natal and postnatal mice to 
isolate connections between body weight or placental mass. A growth retardation cannot 
be assessed because postnatal mice were sacrificed between birth and two days, therefore 
we can not conclusively state that these mice exhibited phenotypic symptoms of AS such 
as seizures, difficulties with motor coordination, neurological, and cognitive 
abnormalities 31,32. 
Imprinting centers (IC) and modes of epigenetic silencing utilize methylation to 
distinguish parental alleles during gametogenesis thru development 33.  PWS and AS 
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imprinting is regulated through a cis acting control center within the SNRPN promoter 34, 
We speculate that variants within the AS-IC or differential methylation patterns between 
the strains causes a silencing of the maternal transmitted SPRET/EiJ alleles and 
expression. Meiotic transmission of the A/J allele by the heterozygous mother results in a 
viable homozygous mouse and is unlikely to be influenced by methylated silencing, 
The TRD on Chr 10 has been previously been reported using C57BL/6J and 
SPRET/EiJ backcrosses 4,11.  The genetic concordance between A/J and C57BL/6J leads 
us to hypothesize that the distorter is the same between the strains. In previous reports the 
Chr 10 TRD extended from Myb to Ifg1 with an apex at Col6a1/Col6a, near D10Mit242 
(41.2 cM) 11.   A similar TRD spanning more than 15 cM and with maximum peak at 
D10Bir9 (30cM) were also reported for an interspecific backcross 4. Reciprocal crosses 
results confirm a preferential selection of heterozygous alleles over homozygous 
C57BL/6J alleles.  
Gene-based theories for TRD include the evolution of a mechanism to maintain a 
hybrid advantage over homozygosity. Alternatively, since this region is not known to be 
an imprinted region, it may be influenced by global strain-specific methylation 
differences resulting in an incompatibility that is not 100% penetrant. If this theory were 
correct, the locus would be expected to be similar between A/J and C57BL/6J and 
different in SPRET/EiJ. The UNC Strain Sequence Identity Interval Viewer (SSI) map 
was used to analyze this interval to confirm that there is minimal genetic diversity 
between A/J and C57BL/6J and maximum diversity between the two strains and 
SPRET/EiJ (Fig. 4) 
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 Epistatic interactions influencing TRD have been reported 8,35. Our study reports 
an independent modifier that is not located in a region of distortion, but has a striking 
effect on Chr 11. The proximal portion of Chr 3 has a slight favoring of A/J alleles, albeit 
not statistically significant to suggest transmission distortion. DMI on Chr 11 is increased 
among N2 progeny with homozygous A/J genotypes on Chr 3.  This suggests that there 
may be a preferential selection of the allelic combination Chr 3AA and Chr 11AS rather 
than a maladaptive incompatibility between Chr 3AA and Chr 11AA. Allelic combinations 
of genes within this region may interact to influence development and/or postnatal 
metabolism and growth.  However, under these conditions S alleles confer a significant 
survival advantage.   
 Interestingly, DMI has been reported in a similar region of Chr 11 in a cross 
between two M. musculus derived strains but lacking the interaction with Chr 3 12. It was 
hypothesized that the female specific deviation may have been due to a modifying locus 
on the X chromosome, interacting with the Om mutant. .Likewise, our data suggests that 
the timing of TRD can be narrowed to a window between birth and weaning. When taken 
into consideration with phenotypic differences and the inability to identify a second locus 
on the X chromosome there remain inconsistencies within their stated hypothesis leaving 
room for additional investigation.   
Although there are now two reports of TRD occurring in a similar region on Chr 
11, the data suggests different mechanism are responsible. Our observed TRD does not 
differentially affect the sexes, and is unlikely to be due to the early embryonic lethal 
DDK syndrome. Evidence does suggest this region maybe in or adjacent to an imprinted 
domain implicating an alternate region of control. Considering in the data reported, the 
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genotype of the least represented progeny are Chr 3AA, Chr 11AA, an unlikely result of 
incompatibility due to the existence of the inbred A/J strain.  Thus it is likely a third 
undetected modifier influences this incompatibility.  An additional study with larger 
sample size may lead to the identification of this modifier.   
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 Table 1. Chi square analysis of the most distorted SNP marker on each chromosome 
displaying deviation from expected inheritance ratios.  A.) Analysis performed on N=140 
samples. B.) To confirm the existence of distortion, analysis was performed on a larger 
sample set of N=235.  C.) Chi square analysis of distorted locus on chromosome 11 that 
epistatically interacts with a SNP locus on chromosome 3.  
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Table 2A.  Chi Square Analysis of Pre-natal Genotype Results. 
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Table 2B. Chi Square Analysis of Post-Natal Genotypes Results.  
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Figure 1A. Segregation of distorted alleles on chromosome 7. Percent distortion 
observed amongst the AJ alleles with cM position of SNP markers.  
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Figure 1B. Segregation of distorted alleles on chromosome 7. Percentage of distortion 
caused when fit to a single-locus model. Open circles represent the distortion observed. 
Darkened squares represent the level of distortion expected with a single distorting locus 
positioned at rs8260829.  The observed recombination distances are recorded on the x-
axis.  
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Figure 2A. Segregation of distorted alleles on chromosome 10. Percent distortion 
observed amongst the M.spretus alleles with cM position of SNP markers.  
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Figure 2B. Percentage of distortion caused when fit to a single-locus model. Open circles 
represent the distortion observed. Darkened squares represent the level of distortion 
expected with a single distorting locus positioned at rs13481119.  The observed 
recombination distances are recorded on the x-axis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  87 
Figure 3A. Segregation of distorted alleles on chromosome 11. Percent distortion 
observed amongst the M.spretus alleles with cM position of SNP markers. 
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Figure 3B. Segregation of distorted alleles on chromosome 11. Percentage of distortion 
caused when fit to a single-locus model. Open circles represent the distortion observed. 
Darkened squares represent the level of distortion expected with a single distorting locus 
positioned at rs13481119.  The observed recombination distances are recorded on the x-
axis.  
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Figure 4. Comparison of IBD regions between A/J, Spret/EiJ and AJ, C57Bl/6J. 
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS 
 
A conservative estimate of the number of genes successfully mapped in humans is 
15-20,000 out of a possible 30,0001.  It is a fair assessment that the identification of many 
of these genes was aided by, or initially localized in a model organism. Mendelian traits 
of single gene inheritance have been more readily identifiable, while the underlying 
causes of the more prevalent diseases in societies have yet to be determined. These 
complex traits disorders, such as cancer susceptibility, are the results of gene-gene, gene-
environment interactions, and weak penetrance in a heterogeneous background. 
The 1942 assertion that lung cancer susceptibility was due to 4 genetic factors 
documents the beginnings of an idealogical shift from “one gene, one enzyme” 2,3. Since 
that time multiple cancer susceptibility loci have been mapped in lung, skin, liver, 
mammary, and colon cancers. Yet Dragani reported Ptprj as one of only 4 cancer 
modifier genes to have been cloned and mapped in humans 4. Ptprj, protein tyrosine 
phosphatase, receptor type J, (Ptprj) has been shown to have a relevant role in the 
development of human cancers. Although a recent report found no associated risk with 
colon cancer susceptibility, Prprj cannot be excluded as a low penetrance modifier 
dependent on intergenic interactions to increase CRC risk.  
It would appear that the stumbling blocks impeding cancer susceptibility 
identification involves narrowing susceptibility loci to valid candidate genes and the 
genetic interactions that increase predisposition.  Multiple techniques are currently being 
applied to the study of complex traits to identify causative genes. These experiments 
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demonstrated the utility of classical genetic mapping approach to localize colon cancer 
susceptibility to genomic intervals, and the ability to utilize emerging technology as a 
candidate gene selection guide and susceptibility network recreation.  
The current study reports 5 novel susceptibility to colon cancer loci, identified 
using a classical genetics mapping approach. The QTL mapping was performed in a Mus 
musculus A/J x Mus spretus SPRET/EiJ backcross, selected for its increased allelic 
diversity and greater likelihood of detecting disease influencing variants. Scc16, a Spretus 
dominant locus, identified in our mapping panel is a moderate contributor to the overall 
phenotype with great potential to also be a clinically relevant modifier in human studies. 
In a second study, expression mapping revealed that Scc16, and previously identified 
Scc15, are located in a dense region of colon specific transcription. A susceptibility 
network anchored to three putative genes, Stat3, Prkca, and Gnb2l1 (Rack1) may 
coordinately influence cancer risk.  
Low penetrance modifier Scc11, located on chromosome 4, was also highlighted 
in our initial study5. This locus was not significant in a whole genome scan, however a 
statistically significant association between genotype and tumor susceptibility was 
captured by point wise analysis. Coincidently, chromosome 4 is the site of a transcription 
cluster with distally located genes mapping near Scc11. Genes in this interval with 
differential expression linked to tumor susceptibility do not seem to be interconnected. 
However, an Scc11 generated network is connected to hub genes in the Scc15/16 
network. Stat1 (Scc11) and Stat3 (Scc15/16), members of the same signal transduction 
family interact to regulate cell survival. In addition, Src, a putative Scc11 network 
component, is regulated at cell cycle checkpoints by downstream modifier, RACK16. 
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SNP variants in any of these interacting genes may adversely effect Src expression 
resulting in increased colorectal cancer risk. 
Transcription mapping allowed us to identify five potentially interacting 
candidate genes by correlating transcript expression with SNP genotypes.  Candidate 
genes were selected underlying QTL confidence intervals. These putative genes are 
thought to influence tumor number, Mef2b (Scc17), tumor load, Ptpn18 (Scc18), 
maximum tumor size, Tax1bp1 (Scc19), and distal tumor position, Ecd (Scc20). These 
genes may interact via Hnf4α, a hepatocyte transcription factor that is integral to 
intestinal development and regulates the expression of numerous genes7,8. We 
hypothesize that a combination of Hnf4α missense mutations and downstream genes 
containing common SNP variants influence tumor progression phenotypes within an at 
risk individual.  
Although transcription mapping is a relatively new technology, we applied an 
additional emerging technique entitled Modulated Modularity Clustering to guide our 
genetic network identification. Genes are grouped into modules according to similarities 
in expression patterns. Modules are therefore highly correlated within groups and 
negatively correlated between groups. We found that most prevalent modules among 
differentially expressed genes contained gene transcripts that have similar biological 
functions.  In particular, module 651 is enriched for genes involved in cancer progression 
and canonical metabolic pathways. Additional modules were enriched for biological 
functions such as inflammatory response, cell cycle progression, gastrointestinal disease, 
and vitamin and mineral absorption. These studies resulted in the generation of several 
putative susceptibility networks based on genomic and transcriptome expression.  
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While the first technology to be widely integrated with genetic mapping was 
transcriptional profiling, proteomic profiling is not far behind. Protein sequence variants 
or single amino acid polymorphisms (SAPs) can be separated into qualitative (variant in 
electrophoretic mobility) and quantitative (variant in presence/absence or protein amount) 
variants. Quantitative protein levels also appear to be determined by allele specific 
sequence of the coding DNA, and thus represent a qualitative phenotype that can be 
genetically mapped. Klose et al demonstrated the ability to resolve more than 1000 
polymorphic soluble brain protein differences between M.musculus and M.spretus using 
2D gels 9. Thus the presence/ absence or protein spot amounts of homozygous and 
heterozygous backcross animals are distinct and can be mapped to protein modifier loci, 
or the protein that acts on the variant spot detected.  
As proteomic, metabolomic, and additional “omic” technologies continue to 
develop, novel bioinformatics methodologies will be required to tractably integrate these 
increasingly large datasets. Future goals will encapsulate the central dogma of molecular 
biology into practice, ‘DNA makes RNA makes protein’.  Combined levels of biological 
information correlated to disease susceptibility will lead to a greater understanding of the 
underlying inter-individual variants that influences cancer and other complex disease 
networks. We hope that by confirming these results at the bench or in human association 
studies will help in the early identification of at risk individuals.  
We discovered an unexpected finding while completing our cancer susceptibility 
study. Three independent events of transmission distortion were detected in our 
interspecific backcross progeny. Deviation from Mendelian allele frequencies is a 
common consequence among interspecific crosses of many species, particularly Mus 
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musculus and Mus spretus. The detection of moderate variations from expected ratios in 
linkage analysis is typically due to sample fluctuations in small crosses. Deviation from 
Mendelian inheritance (DMI) was initially detected on Chr 7, 10 and 11 in a study of 
∼140 animals and reconfirmed in a larger study of ∼235 animals. The distortion causing 
loci were narrowed using a genetic test to determine their origin 10,11. Reports of 
distortion in overlapping chromosomal regions (Chr10, 11) helped guide our hypotheses 
regarding distortion causation 12-14. Efforts are underway to confirm or exclude 
methylation dependent silencing of Angelman Syndrome as the cause of distortion on 
chromosome 7.  
The methylation status of imprinted genes can be assessed by the Sequenom 
Epityper DNA methylation platform. Primers targeting Necdin (Ndn) gene associated 
with Prader Willi Syndrome, Ube3a a gene involved in Angelman Syndrome, and Snrpn 
the imprinting control center are among the pre-validated genes in the Epi panel assays. 
This analysis uses a MALDI-TOF Mass Spectrometer that requires the input of genomic 
sequence to accurately predict the sample methylation status. Because imprinted genes 
have allele specific DNA methylation patterns, the sequence variation between our 
Spretus/EiJ (S) and A/J (A) strains will likely result in genetic variance based 
methylation differences. We have cloned and sequenced the S strain using an E.coli 
vector to ensure we report an accurate percent methylation status. 
Bisulfite treatment of sample DNA causes the deamination of unmethylated 
cytosines converting them to uracil while natively methylated cytosines remain 
unchanged.  Under normal conditions, Snrpn a paternally expressed gene is 
unmethylated. If the distortion is due to Angelman Syndrome we expect (AS)A N2 
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animals to display the opposing methylation patterns in Snrpn and Ube3a. This assay 
should reveal the paternal or maternal specific methylation pattern of each gene. 
We expect the methylation status of these genes to reveal a possible source of the 
transmission distortion on chromosome 7 and provide an additional model to study post-
natal development, growth and metabolism in interspecific backcrosses. 
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Supplementary Table 2.1. SNP Markers used for whole genome typing. 
 
 
 
 
 
  103 
 
 
 
 
 
 
 
 
 
  104 
Supplementary Table 3.1. Illumina and Sequenom SNP Markers used for whole 
genome-typing. 
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Supplementary Table 3.2. Chromosome 4 eQTL cluster. 
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Supplementary Table 3.3. Chromosome 11 eQTL cluster. 
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Supplementary Table 4.1. Illumina and Sequenom SNP Markers used for genotyping 
chromosomes 3, 7, 10, and 11. 
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APPENDIX II 
 
BODY WEIGHT AS A MAPPING QC 
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Quality Control of A/J x SPRET/EiJ Mapping Panel 
 
 Although our initial study was to model sporadic colon cancer, we collected 
additional phenotypic measurements from the (AS)AN2 backcross mice generated from 
A/J (A) and SPRET/EiJ (S) strains. This included a body weight measurement collected 
prior to sacrifice. Body weights of (AS)AN2 have been used to confirm the validity of 
our mapping panel by comparing our results with previously identified obesity QTL in 
mouse backcrosses between Mus musculus domestics C57BL/6J and Mus spretus 
SPRET/EiJ (BSB)1-3. Shared ancestry has resulted in strong genetic concordance between 
the A/J and C57BL/6J strains (Chp 4, Fig 4) and therefore, has been used to reconfirm the 
existence of obesigenic modifiers.  
An initial study by Warden et al, found that Mob1 (Chr 7) and Mob3 (Chr 12) 
influence total body fat1,4.  Femoral fat was influenced by Mob2 (Chr 6) and mesenteric 
fat is attributed to Mob4 (Chr 15)1,4.  In later BSB crosses, Mob1 – Mob4 were re-
confirmed in addition to, two more QTL influencing obesity on Chrs 2 and 16 1-3. Yi et al. 
also demonstrated that each QTL has a main effect on obesity phenotypes and interact 
affecting phenotypic variance2. Chr 2, 7, 12, and 15 influences percent body fat, 
calculated as the total fat mass/carcass weight x 100% 2.  Mob3 interacts with the QTL on 
Chr 2 and 15. The adiposity index (summed fat pad weight / live body weight) is 
controlled by QTL on Chr 2 and 7. Loci on Chr 12 and 16 also influence this phenotype 
through epistatic interactions.  The summation of fat pad weights / live body weight are a 
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measurement of adiposity index.  One main effect QTL on Chr 7, and the interaction of 
loci on Chr 2 and 12 influences total fat mass and body weight2.  
We have been able to replicate QTL on Chr 7 (Mob1) and Chr 12 (Mob3) in the 
(AS)AN2 mice (Supplementary Fig. 1).  In addition, two QTL (Bw1 and 3) were 
identified on the X chromosome. Three loci, Bw1-3, were previously identified in crosses 
(A/J x SPRET/EiJ) x C57BL/6J; (ASB) and (C3H/He x SPRET/EiJ) x C57BL/6J; 
(HSB)5. The intervals defining each QTL are Bw1, DXMit57 (5.9 cM) - DXMit48 (14.2 
cM); Bw2, DXMit109 (27 cM) - DXMit16 (37 cM); and Bw3, DXMit112 (31 cM) - 
DXMit3 (53.1 cM). Our SNP marker rs13483723 maps to 5.9 cM and is within 300 kb of 
the DXMit57. SNP marker rs13484050 maps to 51.82 cM. Bw1 and Bw2 were mapped in 
the HSB population.  Bw3 was mapped in the ASB population.     
We are confident that we have accurately mapped Scc loci due to our ability to 
recapitulate data observed in BSB, ASB, and HSB crosses using body weight as a 
measurement of the obesity phenotype. Our inability to identify all QTL is likely due to 
our phenotypic measurements and does not represent a direct comparison between these 
crosses. Additional differences may also be attributed to mouse strain selection.  
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Supplemental Figure 1.  QC of AJ x SPRET/EiJ SNP Genotyping Panel.    
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